Eli Lilly and Company: Obesity trials

The registry lists 117 Obesity studies with Eli Lilly and Company as lead sponsor. 32 are open to participants now and 29 have results posted.

Phase 1 40Phase 2 21Phase 3 51Phase 4 4No phase 1(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise HealthyNot yet recruitingNCT07915245Phase 1
• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular RiskNot yet recruitingNCT07900633Phase 3
• A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 DiabetesNot yet recruitingNCT07890376Phase 2
• A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 DiabetesNot yet recruitingNCT07881887Phase 1
• A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 DiabetesRecruitingNCT07881458Phase 3
• A Study of EloraTZP in Adult Participants With Obesity Without Type 2 DiabetesNot yet recruitingNCT07881432Phase 3
• Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)RecruitingNCT07817875Phase 3
• A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise HealthyRecruitingNCT07808073Phase 1
• A Study of Eloralintide (LY3841136) in Female Participants With Obesity or OverweightRecruitingNCT07808060Phase 1
• A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or ObesityRecruitingNCT07803744Phase 1
• A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health ProblemsNot yet recruitingNCT07790861Phase 3
• A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular EventRecruitingNCT07783802Phase 2
• A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 DiabetesNot yet recruitingNCT07765511Phase 1
• A Study of Eloralintide (LY3841136) in Participants With Obesity or OverweightRecruitingNCT07738614Phase 1
• A Study of Eloralintide (LY3841136) in Participants With Overweight or ObesityRecruitingNCT07665879Phase 1
• A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise HealthyRecruitingNCT07654972Phase 1
• Pre-approval Expanded Access of Retatrutide (LY3437943)AvailableNCT07629401
• A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or OverweightRecruitingNCT07589608Phase 2
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinRecruitingNCT07392190Phase 3
• A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or OverweightRecruitingNCT07369011Phase 3
• Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightRecruitingNCT07353931Phase 3
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesRecruitingNCT07321886Phase 3
• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesRecruitingNCT07282600Phase 3
• A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)RecruitingNCT07247084Phase 4
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightRecruitingNCT06937099Phase 3
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyRecruitingNCT06937086Phase 3
• A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatideRecruitingNCT06897475Phase 2
• A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)RecruitingNCT06857942Phase 4
• A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesRecruitingNCT06672939Phase 3
• A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)RecruitingNCT06672549Phase 3
• A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)RecruitingNCT06439277Phase 3
• A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightRecruitingNCT06143956Phase 2
• A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 DiabetesTerminatedNCT07030868Phase 2Results posted
• A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or OverweightCompletedNCT06440980Phase 1Results posted
• A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or OverweightCompletedNCT06230523Phase 2Results posted
• A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese ParticipantsCompletedNCT06186622Phase 1Results posted
• A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or OverweightCompletedNCT06124807Phase 2Results posted
• A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related ComorbiditiesCompletedNCT06023095Phase 1Results posted
• A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesCompletedNCT05936151Phase 2Results posted
• A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity DiseaseCompletedNCT05931380Phase 3Results posted
• A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 DiabetesCompletedNCT05872620Phase 3Results posted
• A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesActive, not recruitingNCT05869903Phase 3Results posted
• A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese ParticipantsCompletedNCT05841238Phase 1Results posted
• A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related ComorbiditiesCompletedNCT05822830Phase 3Results posted
• A Study of Tirzepatide (LY3298176) in Pediatric Participants With ObesityCompletedNCT05696847Phase 1Results posted
• Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or ObeseCompletedNCT05616013Phase 2Results posted
• Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep ApneaCompletedNCT05412004Phase 3Results posted
• A Study of LY3502970 in Healthy Overweight and Obese ParticipantsCompletedNCT05313802Phase 1Results posted
• A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related ComorbiditiesCompletedNCT05051579Phase 2Results posted
• A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)CompletedNCT05024032Phase 3Results posted
• A Study of LY3437943 in Participants Who Have Obesity or Are OverweightCompletedNCT04881760Phase 2Results posted
• A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT TrialCompletedNCT04847557Phase 3Results posted
• A Study of Tirzepatide (LY3298176) in Participants With Obesity DiseaseCompletedNCT04844918Phase 3Results posted
• A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight LossCompletedNCT04660643Phase 3Results posted
• A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss ProgramCompletedNCT04657016Phase 3Results posted
• A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are OverweightCompletedNCT04657003Phase 3Results posted
• A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using TirzepatideCompletedNCT04407234Phase 1Results posted
• A Study of Tirzepatide in Overweight and Very Overweight ParticipantsCompletedNCT04311411Phase 1Results posted
• A Study of Tirzepatide (LY3298176) in Participants With Obesity or OverweightCompletedNCT04184622Phase 3Results posted
• A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using TirzepatideCompletedNCT04081337Phase 1Results posted
• A Weight Loss Study in Overweight Men and WomenTerminatedNCT00993421Phase 2Results posted
• A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or ObesityActive, not recruitingNCT07476118Phase 1
• A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or ObesityActive, not recruitingNCT07438444Phase 4
• A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightActive, not recruitingNCT07357415Phase 3
• A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes MellitusActive, not recruitingNCT07299084Phase 1
• A Study of LY3549492 in Healthy Participants and Participants With Overweight or ObesityCompletedNCT07232732Phase 1
• A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightActive, not recruitingNCT07232719Phase 3
• A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise HealthyActive, not recruitingNCT07225556Phase 1
• A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesActive, not recruitingNCT07215559Phase 2
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeActive, not recruitingNCT07153471Phase 3
• A Study of LY4064912 in Healthy Participants and With Overweight or ObesityTerminatedNCT07152002Phase 1
• A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainActive, not recruitingNCT07035093Phase 3
• A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesActive, not recruitingNCT06993792Phase 3
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 DiabetesActive, not recruitingNCT06972472Phase 3
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityActive, not recruitingNCT06972459Phase 3
• A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or OverweightActive, not recruitingNCT06962280Phase 3
• A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1Active, not recruitingNCT06948435Phase 3
• A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 DiabetesCompletedNCT06945419Phase 1
• A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or OverweightCompletedNCT06916091Phase 1
• A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or ObesityCompletedNCT06916065Phase 1
• A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or OverweightActive, not recruitingNCT06914895Phase 3
• A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 DiabetesWithdrawnNCT06901349Phase 2
• A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)Active, not recruitingNCT06864026Phase 4
• A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityActive, not recruitingNCT06859268Phase 3
• A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or OverweightCompletedNCT06824051Phase 1
• A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or OverweightCompletedNCT06683508Phase 2
• A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityActive, not recruitingNCT06662383Phase 3
• A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightCompletedNCT06649045Phase 3
• A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or OverweightActive, not recruitingNCT06643728Phase 2
• A Study of LY3537031 in Overweight, Obese, and Healthy ParticipantsActive, not recruitingNCT06606106Phase 1
• A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 DiabetesCompletedNCT06603571Phase 2
• Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or OverweightCompletedNCT06588296Phase 3
• Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or OverweightCompletedNCT06588283Phase 3
• A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)CompletedNCT06584916Phase 3
• A Study of LY3532226 in Participants With ObesityCompletedNCT06557356Phase 1
• A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With ObesityCompletedNCT06373146Phase 2
• A Study of LY3841136 in Overweight and Obese ParticipantsCompletedNCT06345066Phase 1
• A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943CompletedNCT06313528Phase 1
• A Study of LY3841136 in Japanese Participants With Obesity or OverweightCompletedNCT06297616Phase 1
• A Study of LY3971297 in Healthy ParticipantsCompletedNCT06148272Phase 1